Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestion Rate Clear all
Completed Phase 2 Interventional

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Refametinib (BAY86-9766)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 20, 2026, 2:22 AM EDT
Terminated Phase 4 Interventional Results available

Dosing Study of Amino Acids in Seriously Ill Patients

NCT01923480
View directory record Official record
Conditions
Parenteral Nutrition (No Primary Condition Studied)
Interventions
15% CLINISOL - Sulfite-free (Amino Acid) Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

NCT06906887
View directory record Official record
Conditions
Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer
Interventions
Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation, Pulsed Low-Dose-Rate (PLDR) Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

NCT00803647
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
cetuximab, 5-FU, oxaliplatin, leucovorin
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Loma Linda, California • Orange, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

NCT01137955
View directory record Official record
Conditions
Celiac Disease
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 20, 2026, 2:22 AM EDT
Not yet recruiting Not applicable Interventional

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

NCT07017959
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
LpD3.5 supplementation., Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 20, 2026, 2:22 AM EDT
Withdrawn Not applicable Interventional

Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection

NCT02070107
View directory record Official record
Conditions
Hepatitis C
Interventions
On Plan
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery

NCT00410774
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, gemcitabine hydrochloride, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)

NCT01607255
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Indigo carmine, water (exchange) method, water (exchange) plus dye method, air method
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy

NCT01917513
View directory record Official record
Conditions
Adenoma, Polyps, Colorectal Cancer
Interventions
G-EYE™ colonoscopy, Standard Colonoscopy
Device
Lead sponsor
Smart Medical Systems Ltd.
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 2:22 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

NCT01263574
View directory record Official record
Conditions
Catheter Related Infections, Short Bowel Syndrome
Interventions
70% ethanol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
cetuximab, bevacizumab, gemcitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 20, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 2:22 AM EDT
Withdrawn Not applicable Interventional

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

NCT00547716
View directory record Official record
Conditions
Hepatitis C
Interventions
Omega-3 Fatty Acids, Placebo comparator
Dietary Supplement · Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Computer Aided Detection of Polyps in Colonoscopy

NCT04754347
View directory record Official record
Conditions
Colorectal Polyp
Interventions
Computer Aided Detection device
Device
Lead sponsor
Iterative Scopes, Inc
Industry
Eligibility
40 Years and older
Enrollment
1,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
Boston, Massachusetts • Cambridge, Massachusetts • Plymouth, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 20, 2026, 2:22 AM EDT
Not listed Phase 1 Interventional

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

NCT03094884
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Pulsed Low Dose Radiation, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of the Use of ME-APDS During Colonoscopy

NCT04640792
View directory record Official record
Conditions
Screening Colonoscopy, Surveillance Colonoscopy
Interventions
Screening or Surveillance Conventionall colonoscopy
Procedure
Lead sponsor
Magentiq Eye LTD
Industry
Eligibility
18 Years to 90 Years
Enrollment
952 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 20, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 2:22 AM EDT
Recruiting Phase 4 Interventional

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions
Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
Biological
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study

NCT01955122
View directory record Official record
Conditions
Colon Cancer
Interventions
Tandem Colonoscopy
Device
Lead sponsor
EndoAid
Industry
Eligibility
40 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

NCT00276861
View directory record Official record
Conditions
Colorectal Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy

NCT01954862
View directory record Official record
Conditions
Pain, Colorectal Adenomas, Colorectal Cancer
Interventions
Air Insufflation method., CO2 insufflation, Water Immersion/CO2, Water Exchange/CO2, Water Immersion/AI, Water Exchange/AI
Other
Lead sponsor
Presidio Ospedaliero Santa Barbara
Other
Eligibility
18 Years to 85 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 20, 2026, 2:22 AM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 20, 2026, 2:22 AM EDT